Qi Wang

 Cooley advised Industry Ventures, a top investment firm focusing on venture capital, on its $900 million seventh hybrid fund investing in emerging seed and early-stage funds through primary and early secondary limited partnership interests and direct investments.

Cooley advised D3 Bio – an emerging global biotechnology company that focuses on discovery, development and registration of innovative cancer drugs – on the close of its $62 million Series A+ financing.

Cooley advised HighLight Capital (HLC) on the close of its flagship HLC USD Fund IV at approximately $550 million.

Cooley advised Qiming Venture Partners, a leading venture capital firm in China, on the closing of its oversubscribed Qiming Venture Partners Fund VIII with $2.5 billion in committed capital. Lawyers Jordan Silber, Jingyi Xu, Qi Wang, Sheryl Dai and Hongbo Robert Bao led the Cooley team advising Qiming Venture Partners.

Cooley advised Source Code Capital, a leading Chinese venture capital firm, on the closing of its $1 billion fund, which received backing from both new and old investors. Partners Xun Zeng and Jingyi Xu led the Cooley team advising Source Code Capital.